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Abstract
Background: Independent of other cardiovascular (CV) risk factors, increased arterial stiffness has been established
as a predictor of morbidity and mortality. The main aim of this study was to investigate the impact of diabetes on
arterial stiffness in a representative sample of an urban Brazilian population plus Amerindians.
Methods: A total of 1,415 individuals from the general population were randomly selected plus 588 Amerindians
from a native community in Brazil. In addition, a sub-sample of 380 individuals from the general population had
5-year follow-up data. Pulse wave velocity (PWV) was measured with a non-invasive automatic device (Complior,
Colson; Garges les Gonesses, France) and increased arterial stiffness was defined as PWV ≥ 12 m/s.
Results: In the overall group, diabetic individuals had higher frequencies of increased arterial stiffness and
hypertension. They also had higher values of PWV, body mass index, total cholesterol, triglycerides, systolic and
diastolic blood pressures compared to non-diabetic individuals (p < 0.01). In an analysis stratified by hypertension,
PWV values and increased arterial stiffness frequency were higher in diabetic individuals in both groups
(hypertensive and non-hypertensive) (p < 0.05). Furthermore, higher risk for increased arterial stiffness was observed
in the diabetic individuals from the overall group (OR = 2.27; CI = 1.47-3.52, p < 0.001) and from the hypertensive
group (OR = 2.70; CI = 1.58-4.75, p < 0.001), adjusted for covariates. Regarding the ethnic stratification, diabetic
individuals from Amerindian, White, and Mulatto (mixed-race) groups had higher PWV values and a greater
frequency of increased arterial stiffness compared to non-diabetic individuals. Both diabetic and non-diabetic
individuals had higher PWV values after 5 years. There was no significant difference in the 5-year PWV progression
in diabetic compared to non-diabetic individuals.
Conclusions: These results confirm, in a sample of Brazilian population, that the presence of diabetes is associated
with increased arterial stiffness and it may contribute in part to increased cardiovascular risk in diabetic patients.
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Introduction
Increased central arterial stiffness is an important deter-
minant of cardiovascular (CV) disease risk [1,2]. Several
epidemiological studies reported that increased arterial
stiffness predicts mortality and morbidity, independently
of other CV risk factors [3-6]. Arterial stiffness measured
through carotid-femoral pulse wave velocity (PWV), a
gold standard method, has been associated with mea-
sures of subclinical CV disease [7]. Furthermore, clinical
studies have shown that the arterial stiffness increases
with aging or various pathological processes associated
with hypertension, metabolic syndrome, chronic renal
disease, and diabetes [8-12].
Diabetes mellitus is associated with increased risk
for CV disease and mortality. The pathophysiological
mechanism underlying these associations has not been
fully elucidated. However, arterial stiffness may be
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one important pathway linking diabetes to increased CV
risk [13,14]. Diabetes may enhance arterial stiffness
through pathological changes in the vascular bed, such
as reduced nitric oxide bioavailability, increased oxida-
tive stress, chronic low-grade inflammation, increased
sympathetic tone and changes in type or structure of
elastin and/or collagen in the arterial wall [14-16].
Based on the fact that arterial stiffness measure is an
important clinical marker for CV diseases and that dia-
betes is recognized as a risk factor for CV diseases, our
main aim was to investigate the impact of diabetes on
arterial stiffness in a representative sample of the urban
Brazilian population plus Amerindians.
Methods
Study population
A study of risk factors for CV diseases was performed in
the urban population of Vitoria, Brazil, using the WHO-
MONICA project guidelines [17]. The survey was con-
ducted with just one resident of the home selected from
the age group of the study. The resident selection process
was carried out by means of a randomization mechanism.
The research was provided to the individual selected at
each home that was then invited to participate in the
study, after giving his or her consent. The selected indivi-
duals were asked to attend the Cardiovascular Inves-
tigation Clinic of the University Hospital for general,
laboratory, and clinical tests to be performed on the fol-
lowing day. Firstly, selection of 2,268 residential homes
located in Vitoria was made. Of the participants invited,
1,663 individuals (either gender, 25–64 years of age) were
further evaluated and attended the clinic visit. Here, data
from 1,415 participants were evaluated. After 5 years, a
follow-up to perform clinical tests was done in 380
patients. We also recruited 588 Amerindians to known
specific characteristic of this ethnic group, derived from
two different groups (Guarani and Tupinikin) living at the
Aracruz Indian Reserve, Espirito Santo State on the
southeast Brazilian coast [18]. This study was approved by
the ethics committee for Research on Human Subjects of
the Espirito Santo Federal University and National Ethics
Committee for Human Research (CONEP Register Num-
ber 4599).
Demographic data
General data were obtained through a structured inter-
view. Weight and height were measured according to a
standard protocol, and body mass index (BMI) was cal-
culated. Subjects of the urban population underwent
ethnic classification according to a validated question-
naire for the Brazilian population, and they were classi-
fied as White, Black, or Mulatto (considered racially
mixed subjects, especially between White and Black)
[19]. Individuals living on the Indian reserve of Aracruz
were ethnically classified as Amerindians if they reported
having at least grandparents living at the reserve.
Laboratory determinations
Blood triglycerides (TG), total cholesterol (TC), high-
density lipoprotein cholesterol (HDL-C), low-density
lipoprotein cholesterol (LDL-C), and fasting glucose
were evaluated by standard techniques in 12-h fasting
blood samples. Diabetes mellitus was diagnosed by
the presence of fasting glucose ≥ 126 mg/dL and/or
antidiabetic drug use [20]. Hyperlipidemia was de-
fined as TC ≥ 240 mg/dL, LDL-C ≥ 160 mg/dL, and/or
use of hypolipidemic drugs [21,22].
Blood pressure phenotypes and PWV determinations
Blood pressure was measured while the patient was in
the sitting position with the use of a standard mercury
sphygmomanometer on the left arm after a 5-minute
rest [18]. The first and fifth phases of Korotkoff sounds
were used for systolic blood pressure (SBP) and dia-
stolic blood pressure (DBP), respectively. The SBP and
DBP were calculated from two readings with a minimal
interval of 10 minutes apart. The mean blood pressure
(MBP) was calculated as the mean pulse pressure added
to one-third of the DBP [23]. Hypertension was defined
as mean SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg
and/or antihypertensive drug use [24].
Carotid-femoral PWV was analyzed with an automatic
device (Complior; Colson) by an experienced observer
blinded to clinical characteristics. Briefly, common
carotid artery and femoral artery pressure waveforms
were recorded noninvasively using a pressure-sensitive
transducer (TY-306- Fukuda; Fukuda; Tokyo, Japan).
The measurement of PWV was performed in one period
of 10–15 seconds and the carotid-femoral distance was
used for the PWV assessment. The distance between the
recording sites (D) was measured, and PWV was auto-
matically calculated as PWV =D/t, where (t) means
pulse transit time. Measurements were repeated over 10
different cardiac cycles [23]. A variable for increased ar-
terial stiffness was defined as PWV ≥ 12 m/s [25]. The
validation of this automatic method and its reproduci-
bility has been previously described [26].
Statistical analysis
Continuous variables data are presented as mean and
standard deviation and categorical variables as frequen-
cies. χ2-test was performed for the comparative analysis
of the frequencies of gender, hypertension, ethnicity, and
increased arterial stiffness according to the presence or
absence of diabetes. The Student t test was used to com-
pare age, BMI, biochemical data, blood pressure pheno-
types, and PWV according to diabetes. Paired samples
Student t test for repeated measures was performed to
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compare the PWV values during 5-year follow-up. In
addition, comparisons stratified by ethnicity and hyper-
tension were performed. Logistic regression analyses
were performed to evaluate the association of diabetes
mellitus with increased arterial stiffness plus adjustment
for covariates. Also, logistic models were performed to
measure the interaction between diabetes mellitus and
hypertension on increased arterial stiffness. PWV values
were adjusted for age, gender, MBP, ethnicity, BMI, and
smoking. Arterial stiffness variable was analyzed in two
models using ANCOVA (model 1: adjusted for age,
gender, and MBP; and model 2: adjusted for age, gender,
MBP, ethnicity, BMI, smoking, and dyslipidemia). All
statistical analyses were carried out using SPSS software
(version 16.0, IBM, New York, NY), with the level of
significance set at p ≤ 0.05.
Results
General data of the study sample
Of the 2,003 individuals, 136 (6.8%) had diabetes. The
distribution of gender (p = 0.11) and smokers (p = 0.48)
between diabetic and non-diabetic groups was similar.
The percentage of diabetic individuals in the Amerin-
dian group was lower than that in the White, Mulatto,
and Black groups (p = 0.01). Hypertension (p < 0.001),
hyperlipidemia (p < 0.001), and increased arterial stiff-
ness (p < 0.001) frequencies were higher in diabetic
compared to non-diabetic individuals (Table 1). Age
(p < 0.001), BMI (p < 0.001), total cholesterol (p = 0.004),
triglycerides (p < 0.001), SBP (p < 0.001), DBP (p =
0.004), and PWV (p < 0.001) were higher in diabetic
compared to non-diabetic individuals. In addition,
individuals with diabetes had lower HDL-cholesterol
(p < 0.001) compared to non-diabetic individuals (Table 1).
Analysis of the increased arterial stiffness and PWV
according to diabetes and stratified by hypertension
status
Of the 2,003 subjects, 767 (38.3%) had hypertension.
Overall, individuals with diabetes had higher PWV than
non-diabetic individuals (11.6 ± 2.7 m/s and 9.3 ± 2.1 m/s;
p < 0.001). In addition, the frequency of increased arterial
Table 1 General characteristics, biochemical, and hemodynamic data of the general population plus Amerindian
Variables Diabetics (n136) Non-diabetics (n1867) p value
Age (years) 52.7 ± 10.0 41.8 ± 12.3 <0.001
Gender, female (%) 60.3 531 011
Race/color (%)
Amerindian 4.1 95.9
White 7.1 92.9 0.01
Intermediate 8.6 91.4
Black 6.8 93.2
Hypertension (%) 757 354 <0.001
Increased arterial stiffness (%) 39.0 11.7 <0.001
Smokers (%) 274 236 048
Hyperlipidemia (%) 45.0 24.4 <0.001
Body mass index (Kg/m2) 29.6 ± 5.9 25.7 ± 4.5 <0.001
Total cholesterol (mg/dL) 212.1 ± 69.7 199.6 ± 50.0 0.004
LDL-C (mg/dL) 1326 ± 46.3 128.8 ± 44.4 0.32
HDL-C (mg/dl) 42.4 ± 10.4 46.8 ± 13.4 <0.001
Triglycerides (mg/dL) 194.1 ± 233.9 122.3 ± 101.2 <0.001
Systolic blood pressure (mmHg) 134.9 ± 213 125.3 ± 20.1 <0.001
Diastolic blood pressure (mmHg) 85.2 ± 14.0 81.6 ± 14.1 0.004
Pulse wave velocity (m/s) 11.6 ± 2.7 9.3 ± 2.1 <0.001
Continuous data are expressed as mean ± standard deviation.
HDL-C: high density lipoprotein; LDL-C: low density lipoprotein.
Biochemical data and blood pressures were adjusted for age, gender, and ethnicity.
Analysis of PWV variable is adjusted for age, gender, mean blood pressure (MBP), ethnicity, body mass index, and smoking.
Ethnicity is categorized as Amerindian, White, Mulatto (Brown or “pardo” in Portuguese, person with admixture between White and Black) and Black.
Hypertension =mean systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg or use of anti-hypertension drugs.
Increased arterial stiffness frequency = pulse wave velocity (PWV) ≥ 12m/s.
Diabetes = fasting glucose ≥ 126 mg/dL and/or use of hypoglycemic drugs.
Dyslipidemia = total cholesterol ≥ 240 mg/dL, LDL-C ≥ 160 mg/dL, and/or use of hypolipidemic drugs.
Individuals who had ever smoked more than five cigarettes per day for the last year were classified as smokers.
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stiffness was also higher in diabetic compared to non-
diabetic individuals (39.0% and 11.7%; p < 0.001)
(Table 2). In both non-hypertensive and hypertensive
groups, the diabetic individuals had higher PWV values
(p = 0.03, p < 0.001; respectively) and increased arterial
stiffness frequency (p = 0.02, p < 0.001; respectively)
(Table 2).
Regarding the analysis of the odds ratio of increased
arterial stiffness, the individuals with diabetes in the total
group had higher risk for increased arterial stiffness
compared to non-diabetic individuals, even after adjust-
ment for model 1 plus hypertension (OR 2.27, 95% CI
1.47-3.52) or for model 2 plus hypertension (OR 2.45,
95% CI 1.42-3.76) (Table 2). Furthermore, in the hyper-
tensive group, diabetic individuals had increased risk for
increased arterial stiffness compared to non-diabetic
individuals in both models 1 and 2 (OR 2.23, 95% CI
1.41-3.52 and OR 2.75, 95% CI 1.53-4.81, respectively)
(Table 2). However, in the non-hypertensive group, the
presence of diabetes did not determine a significantly
risk for increased arterial stiffness (Table 2).
In a logistic model, interaction between diabetes and
hypertension on arterial stiffness was not significant
(p = 0.62). However, a significant odds ratio was ob-
served in patients with both phenotypes (Figure 1).
Analysis of the increased arterial stiffness and PWV
according to diabetes and stratified by ethnicity
In the study population, 588 (29.4%) were Amerindians,
533 (26.6%) Whites, 765 (38.2%) Mulatto, and 117
(5.8%) Blacks. Diabetic individuals from Amerindian,
White, and Mulatto groups had higher PWV values
(p = 0.02, p = 0.007, p < 0.001, respectively) and fre-
quency of increased arterial stiffness (p < 0.001, p =
0.001, p < 0.001, respectively) compared to non-diabetic
individuals (Table 3). However, in the Black group, no
difference in PWV values (p = 0.14) and in increased
arterial stiffness frequency (p = 0.16) was observed
according to diabetes (Table 3).
Table 2 Analysis of the increased arterial stiffness
according to diabetes mellitus of the general population
plus Amerindian
Diabetics Non-diabetics p value
(n = 136) (n = 1867)
PWN (m/s) 11.6 ± 2.2 8.5 ± 1.7 <0.001
Increased stiffness (%) 39.0 11.7 <0.001
Models OR 95% CI p value
Adjusted*¥ 2.27 1.47-3.52 <0.001
Adjusted**¥ 2.45 1.42-3.76 <0.001
Stratified by hypertension
PWN (m/s) 10.3 ± 2.2 8.5 ± 1.7 0.03
Increased stiffness (%) 12.1 3.1 0.02
Models OR 95% ± p value
Adjusted* 1.65 0.53-5.16 0.39
Adjusted** 1.33 0.38-4.70 0.62
Hypertensive Diabetics Non-diabetics p value
(n = 103) (n = 664)
PWN (m/s) 12.3 ± 2.7 10.9 ± 2.1 <0.001
Increased stiffness (%) 47.6 25.9 <0.001
Models OR 95% CI p value
Adjusted* 2.23 1.41-3.52 0.001
Adjusted** 2.75 1.53-4.81 <0.001
Continuous data are expressed as mean ± standard deviation.
Increased arterial stiffness = pulse wave velocity (PWV) ≥ 12m/s and, this was
used as dependent variable in the logistic model.
Analysis of PWV variable is adjusted for age, gender, mean blood pressure
(MBP), ethnicity, body mass index (BMI), and smoking.
* Model 1: adjusted for age, gender, and MBP.
** Model 2: adjusted for age, gender, MBP, ethnicity, BMI, smoking,
and dyslipidemia.
¥Adjusted by model 1 plus hypertension or by model 2 plus hypertension.
Hypertension =mean systolic blood pressure ≥ 140 mmHg and/or diastolic
blood pressure ≥ 90 mmHg or use of anti-hypertension drugs.
Diabetes = fasting glucose ≥ 126 mg/dL and/or use of hypoglycemic drugs.
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Figure 1 Logistic model arterial stiffness odds ratio using
diabetes mellitus and hypertension phenotypes. Increased
arterial stiffness = pulse wave velocity≥ 12m/s. Diabetes mellitus and
hypertension phenotypes are categorized as 0 (non-diabetic and
non-hypertensive group), 1 (diabetic and non-hypertensive group; p
= 0.02), 2 (non-diabetic and hypertensive group; p < 0.001), and 3
(diabetic and hypertensive group; p < 0.001).
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Analysis of the PWV values in a 5-year follow-up
according to diabetes status
Three hundred and eighty individuals from the general
population had a 5-year follow-up in which PWV values
were analyzed. Regarding baseline characteristics of this
subgroup, the variables gender (p = 0.15), age (p = 0.10),
BMI (p = 0.22), race (p = 0.38), smoking (p = 0.55) and
PWV (p = 0.99) were not different between groups. Both
diabetic (n = 25) and non-diabetic (n = 355) individuals
had higher PWV values after 5 years. Non-diabetic indi-
viduals increased PWV by a mean of 0.4 m/s, while dia-
betic individuals increased PWV by a mean of 1.5 m/s
(both p = 0.03, performed by paired samples t test
repeated measures). Despite the progression of values
being numerically higher in the diabetic group compared
with the non-diabetic group, it was not significantly
different (Figure 2).
Discussion
Our data show that diabetes status is significantly associ-
ated with PWV measurement and arterial stiffness
phenotype even after adjustment for covariates. This re-
lationship is well assessed in the literature. However, to
the best of our knowledge, this is the first study to inves-
tigate the association stratified for ethnicity in an admix-
ture population and for hypertension in individuals from
an urban Brazilian population plus Amerindians.
The role of diabetes in CV risk and disease has been
widely investigated. Indeed, it is generally assumed that a
subject with type 2 diabetes has a similar CV risk as that
of a non-diabetic individual who has sustained a myo-
cardial infarction [27]. Our data demonstrate that subjects
with diabetes had higher PWV values and higher risk for
increased arterial stiffness compared to non-diabetic indi-
viduals. Corroborating our findings, Li et al. [28] reported
that individuals with impaired glucose tolerance and
those with diabetes had higher brachial-ankle PWV
values compared to individuals with normal glucose
tolerance. Galler et al. [29] identified similar findings in
children and adolescents with type I diabetes compared
to healthy children. Other recent studies also demonstrate
the impact of diabetes on arterial stiffness [30-32]. Fur-
thermore, an interesting study showed that individuals
with diabetes with satisfactory glycemic control had higher
levels of circulating endothelial progenitor cells and had
lower arterial stiffness [33].
Many of the pathophysiological mechanisms respon-
sible for vascular dysfunction in diabetes are determined
by hyperglycemia, which is associated with the activation
of pro-inflammatory transcription factors and increased
oxidative stress, leading to vasculopathy [34]. Increased
advanced glycation end-product levels may alter the im-
portant matrix of molecules in the vessel wall [35]. In
addition, some studies show endothelial and vascular
smooth muscle cell dysfunction in diabetic individuals
compared to controls indicating that type 2 diabetes
mellitus may both reduce the bioavailability of endothe-
lial nitric oxide and attenuate sensitivity of the smooth
muscle cells to nitric oxide [36-39]. All these pathways
appear to be involved in mediating the hyperglycemia-
associated arterial stiffness.
Table 3 Analysis stratified by ethnicity for the pulse wave
velocity and increased arterial stiffness according to
diabetes mellitus
Diabetics Non-diabetics p value
Amerindian (n = 24) (n = 564)
PWV (m/s) 11.2 ± 3.1 8.5 ± 2.0 0.02
Increased arterial stiffness (%) 33.3 10.1 <0.001
White (11.5 ± 2.3) 9.8 ± 1.9 0.007
Increased stiffness (%) 31.6 12.3 0.001
Intermediate (n = 66) (n = 699)
PWV (m/s) 11.5 ± 2.9 9.5 ±2.1 <0.001
Increased arterial stiffness (%) 45.5 11.6 <0.001
Black (n = 8) (n = 109)
PWV (m/s) 12.3 ± 1.6 10.2 ± 2.5 0.14
Increased arterial stiffness (%) 37.5 17.4 0.16
PWV (m/s) 12.3 ± 1.6 10.2 ± 2.5 0.14
Increased arterial stiffness (%) 37.5 17.4 0.16
Analysis of PWV variable is adjusted for age, gender, mean blood pressure,
hypertension, body mass index, and smoking.
Ethnicity is categorized as Amerindian, White, Mulatto (Brown or “pardo” in
Portuguese, person with admixture between White and Black) and Black.
Hypertension =mean systolic blood pressure ≥ 140 mmHg and/or diastolic
blood pressure ≥ 90 mmHg or use of anti-hypertension drugs.
Increased arterial stiffness = pulse wave velocity (PWV) ≥ 12m/s.
Diabetes = fasting glucose ≥ 126 mg/dL and/or use of hypoglycemic drugs.
PWV (m/s)
0 5
10.8 2.3 12.3 2.4
9.8 2.1 10.1 2.3
p = 0.03
p = 0.03
Follow -up 
(years)
Figure 2 PWV values in a 5-year follow-up to the diabetes. The
dotted line represents the individuals with diabetes (n = 25) and the
solid line represents individuals without diabetes (n = 355) during
the follow-up. PWV (pulse wave velocity) are expressed as mean ±
standard deviation. Analysis of PWV was performed by paired
samples t test repeated measures.
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Diabetes and hypertension are closely associated, and it
is difficult to isolate the independent and additive effects
of these conditions on PWV values. Also, blood pressure
measure is frequently higher in type 2 diabetes than in
individuals without diabetes [40]. Moreover, analysis of
the Framingham cohorts [41] showed that diabetic indi-
viduals with hypertension had higher rates of all-cause
mortality and cardiovascular disease events than subjects
with diabetes alone. In addition, Cardoso et al. [42] stu-
dying patients with type 2 diabetes showed that severity of
hypertension, reflected by higher 24-hour pulse pressure
and the greater number of anti-hypertensive drugs in use,
is a risk predictor to arterial stiffness. Corroborating our
findings, Tedesco et al. [43], analyzing the synergistic
interaction of diabetes with hypertension on arterial stiff-
ness, found significantly higher PWV in patients with both
hypertension and diabetes compared to patients with dia-
betes or hypertension alone. The results from our study
confirm that both diabetes and hypertension increase risk
for increased arterial stiffness and that having two condi-
tions led to even higher predicted PWV levels. In the non-
hypertensive group, the absence of significant association
with risk for increased arterial stiffness can be explained
by the small number of diabetic individuals.
The impact of ethnic or racial differences on preva-
lence and morbidity of CV disease have already been
reported [44,45]. Studies have shown that the preva-
lence of and mortality from hypertensive heart disease,
stroke, and renal disease are higher among African-
than Caucasian-descent individuals in the United States
[44-46]. In addition, the African Americans have a
higher prevalence and incidence of hypertension and
end-organ damage than Whites have [47,48]. However,
studies demonstrating the impact of diabetes on arterial
stiffness within different ethnic groups in admixture popu-
lations are scarce. Strain et al. [49], studying Europeans
and African Caribbeans, demonstrated that the diabetic
individuals had higher arterial stiffness values compared
to non-diabetic individuals independently of ethnicity.
But, African Caribbeans with diabetes had increased stiff-
ness compared to Europeans. Similarly to the previously
mentioned comorbidities, ethnicity also is associated with
arterial stiffness phenotype. A recent study from our
group demonstrates that the individuals of African-
descent had higher arterial stiffness and hypertension
frequencies, while Amerindians had lower frequencies
[23]. Here, inclusion of Amerindian individuals permitted
assessment of a group with a lower frequency of hyper-
tension beside genetic background. Our findings in an
admixture population demonstrated a significant asso-
ciation between diabetes and increased arterial stiffness
according to ethnic groups (Amerindian, White, and
Mulatto), except in the Black group. Probably, this non-
significant finding was the result of the small number of
diabetic individuals in the Black group, but the numerical
data were equally different. Amerindian group had also
small number of diabetic individuals.
Regarding the analysis of the PWV values in a 5-year
follow-up according to diabetes status, PWV increased 0.4
m/s in the non-diabetic group and 1.5 m/s in the diabetic
group. Even these values being statistically similar -
probably for the small number of diabetic patients, short-
term of follow-up, and possible good treatment in the
diabetic group – one can expect this increase to have sig-
nificant clinical consequences. Indeed, a current study re-
ports that an increase by a single unit (m/s) leads to a 15%
higher risk of mortality from cardiovascular events [6].
Our study had some limitations. First, three measure-
ments of office blood pressure were performed during a
single study visit for hypertension classification, besides
the use of antihypertensive drugs and a previous diagnosis.
Also, diabetes was diagnosed by the presence of a single
measurement of fasting glucose ≥126 mg/dL and/or
antidiabetic drug use and a previous diagnosis. Both
hypertension and diabetes diagnosis criteria could increase
the likelihood of misclassification. Second, even though
statistical adjustments have been made for potential
confounders, in two models, residual confounding cannot
be excluded. Third, our study is cross-sectional and it only
provides exploratory data regarding casual relations that
reaffirm the relationship between diabetes and increased
arterial stiffness. We also did not collect variables, such
as diabetes duration and previous renal or cardiovas-
cular diseases. However, it may reaffirm the hypothesis
that arterial stiffness acts as a trigger of CV disease in
diabetic individuals. Fourth, the measurement of PWV
was performed in one period of 10–15 seconds and the
real carotid-femoral distance was used for the PWV
assessment. These criteria differ, in part, from the new
consensus [50].
Conclusions
In conclusion, our results confirm, in a sample of Brazilian
population, that the presence of diabetes is associated with
increased arterial stiffness and it may contribute in part to
increased cardiovascular risk in diabetic patients.
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